Radiotherapy and Nuclear Medicine Unit, Istituto Oncologico Veneto-IRCCS, Padova, Italy.
Thyroid. 2011 Aug;21(8):921-5. doi: 10.1089/thy.2010.0335. Epub 2011 May 19.
Pituitary metastases are found in about 1% of all pituitary resections. They often derive from breast, lung, and gastroenteric tract adenocarcinomas, very rarely from thyroid carcinoma. Presenting symptoms of thyroid carcinoma metastatic to the pituitary gland are usually chiasmatic with central neurological impairment due to space-occupying expansion in the parasellar region. Hypopituitarism is more often associated with papillary and medullary rather than follicular thyroid carcinoma (FTC). Here we describe a patient with pituitary metastasis from FTC who had hypopituitarism with thyrotropin (TSH) deficiency.
A 61-year-old woman, who presented with visual deficits and pain to the right orbit, was found on magnetic resonance imaging to have a large mass involving the pituitary gland. She was found to have pituitary insufficiency based on corticotropin-releasing hormone and TSH-releasing hormone testing. Transnasopharyngeal biopsy of the mass revealed metastases from FTC. After total thyroidectomy, which confirmed widely invasive FTC, the patient underwent external beam radiation therapy of the metastases for progressive neurological symptoms and an increase in orbit pain. Since endogenous TSH production was insufficient, we used recombinant human TSH (rhTSH) as preparation for a series of radioiodine treatments. rhTSH administration, followed by 7.4 GBq of (131)I, was repeated seven times over a 10-year period. This was associated with a marked decrease in serum thyroglobulin levels accompanied by substantial clinical improvement, but after 7 years disease progression occurred.
Seven patients with pituitary metastases from FTC have been reported. In all cases, some neurological signs and symptoms related to mass effect were reported, but no pituitary insufficiency was described. This may be the first case of FTC with metastases to the pituitary causing hypopituitarism. It seems likely that management of such cases could be limited to biopsy to confirm thyroid carcinoma, rather than more extensive surgery, and that this could be followed by multiple treatments with rhTSH followed by (131)I.
垂体转移瘤在所有垂体切除术中约占 1%。它们通常来源于乳腺、肺和胃肠道腺癌,很少来源于甲状腺癌。由于鞍旁区域占位性扩张导致的中枢神经系统损伤,甲状腺癌转移至垂体的表现通常为视交叉。促甲状腺激素(TSH)缺乏症与垂体功能减退症更为相关的是甲状腺癌的乳头状和髓样癌,而非滤泡状甲状腺癌(FTC)。在这里,我们描述了一位 FTC 垂体转移患者,该患者存在促甲状腺激素缺乏的垂体功能减退症。
一名 61 岁女性,因右眼眶疼痛和视力减退就诊,磁共振成像显示垂体有一大肿块。基于促肾上腺皮质激素释放激素和 TSH 释放激素检测,她被发现存在垂体功能不全。肿块的经鼻蝶活检显示 FTC 转移。在广泛浸润性 FTC 的全甲状腺切除术之后,由于进行性的神经症状和眼眶疼痛增加,患者接受了转移灶的外照射治疗。由于内源性 TSH 产生不足,我们使用重组人 TSH(rhTSH)为一系列放射性碘治疗做准备。rhTSH 给药后,10 年内重复进行了 7 次 7.4GBq 的(131)I 治疗。这与血清甲状腺球蛋白水平的显著降低以及临床症状的显著改善有关,但 7 年后出现疾病进展。
已有 7 例 FTC 垂体转移患者的报告。在所有病例中,都报告了一些与肿块效应相关的神经症状和体征,但未描述垂体功能不全。这可能是首例 FTC 转移至垂体导致垂体功能减退症的病例。似乎这种情况下的治疗可能仅限于活检以确认甲状腺癌,而不是更广泛的手术,并且可以随后进行多次 rhTSH 治疗,然后进行(131)I 治疗。